We are live on ! Find out more
PRAX icon

Praxis Precision Medicines
PRAX

103 hedge funds and large institutions have $108M invested in Praxis Precision Medicines in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 40 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $95.6M → $108M (+$12.2M)

0.26% more ownership

Funds ownership: 6.16% → 6.43% (+0.26%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 108 → 103 (-5)

22% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 23

35% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 40

Holders
103
Holders Change
-5
Holders Change %
-4.63%
% of All Funds
1.66%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
18
Increased
26
Reduced
40
Closed
23
Calls
$4K
Puts
–
Net Calls
+$4K
Net Calls Change
-$537K

Top Buyers

1
BBA
Baker Bros. Advisors
New York
+$3.81M
2
KCM
Kingdon Capital Management
New York
+$3.53M
3
Bank of America
Bank of America
North Carolina
+$3.08M
4
OCA
Octagon Capital Advisors
New York
+$1.66M
5
Verition Fund Management
Verition Fund Management
Connecticut
+$1.59M

Top Sellers

1
VVA
Vida Ventures Advisors
Massachusetts
-$3.06M
2
Millennium Management
Millennium Management
New York
-$1.69M
3
PHS
PFM Health Sciences
California
-$1.42M
4
GCM
Graham Capital Management
Connecticut
-$1.06M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$926K
Name Holding Trade Value Shares
Change 		Change in
Stake
Blackstone Inc
1
Blackstone Inc
New York
$11.6M – – –
EAM
2
Eventide Asset Management
Massachusetts
$8.37M – – –
BlackRock
3
BlackRock
New York
$7.07M -$566K -18,163 -8%
KCM
4
Kingdon Capital Management
New York
$6.8M +$3.53M +113,333 +147%
PHS
5
PFM Health Sciences
California
$6.61M -$1.42M -45,404 -20%
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$5.37M – – –
BBA
7
Baker Bros. Advisors
New York
$4.36M +$3.81M +122,021 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$4.25M -$37.5K -1,204 -1%
Verition Fund Management
9
Verition Fund Management
Connecticut
$3.98M +$1.59M +51,071 +85%
EC
10
EcoR1 Capital
California
$3.77M +$185K +5,933 +6%
Bank of America
11
Bank of America
North Carolina
$3.61M +$3.08M +98,762 +4,423%
VVA
12
Vida Ventures Advisors
Massachusetts
$3.5M -$3.06M -97,977 -50%
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$3.22M +$690K +22,124 +32%
AG
14
Artal Group
Luxembourg
$2.86M – – –
7IH
15
72 Investment Holdings
Connecticut
$2.35M – – –
State Street
16
State Street
Massachusetts
$2.11M +$21.7K +696 +1%
OCA
17
Octagon Capital Advisors
New York
$1.9M +$1.66M +53,333 New
HMC
18
Harvard Management Company
Massachusetts
$1.85M – – –
Citadel Advisors
19
Citadel Advisors
Florida
$1.8M -$677K -21,718 -30%
Goldman Sachs
20
Goldman Sachs
New York
$1.71M -$838K -26,877 -36%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$1.65M +$122K +3,925 +9%
ABG
22
Ally Bridge Group
New York
$1.5M +$1.31M +42,039 New
MB
23
MPM BioImpact
Massachusetts
$1.45M +$1.27M +40,667 New
D.E. Shaw & Co
24
D.E. Shaw & Co
New York
$1.37M +$604K +19,358 +102%
Two Sigma Advisers
25
Two Sigma Advisers
New York
$1.07M -$117K -3,740 -11%
1
2 3 4 5

PRAX Hedge Fund Activity: Q4 2022 in Review

103 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q4 2022, worth a combined $108M — up 13% from $95.6M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of PRAX and 18 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 26 added.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.81M. The largest seller was Vida Ventures Advisors, cutting an estimated $3.06M.

  • 103 institutional investors held Praxis Precision Medicines (PRAX) as of Q4 2022, down from 108 in Q3 2022.
  • Funds reported $108M of Praxis Precision Medicines stock for Q4 2022, up 13% quarter-over-quarter.
  • 18 funds opened new Praxis Precision Medicines positions in Q4 2022 and 23 closed out, a net change of -5 holders.
  • The largest Praxis Precision Medicines buyer in Q4 2022 was Baker Bros. Advisors, an estimated $3.81M added.
  • The largest Praxis Precision Medicines seller in Q4 2022 was Vida Ventures Advisors, an estimated $3.06M sold.

Based on aggregated 13F filings for Q4 2022.